Recent developments for Arbutus Biopharma include a significant patent dispute settlement, changes in strategic partnerships, and notable financial performance updates.

• On March 4, 2026, Arbutus was involved in a $2.25 billion settlement deal to resolve patent disputes with Moderna and Roivant, impacting the company and related entities [N2].
• On March 4, 2026, notable option activity was observed in Arbutus shares, indicating market interest [N1].
• On January 16, 2026, Arbutus shares fell 19% following the revocation of a European patent, highlighting ongoing intellectual property challenges [N3].
• In November 2025, Chardan Capital maintained a buy recommendation on Arbutus, reflecting positive analyst sentiment [N4].
• In August 2025, Arbutus reported a 529% surge in Q2 revenue, driven by milestone payments and collaboration income [N7].
• Also in August 2025, the company reported Q2 earnings and revenue results that exceeded expectations [N8].
• In June 2025, Arbutus reacquired global rights to imdusiran after concluding its partnership with Qilu Pharmaceutical [N5].
• In May 2025, Arbutus reported a Q1 loss but topped revenue estimates, indicating operational progress [N5].

Arbutus has demonstrated operational focus by streamlining its research efforts and concentrating on advancing key clinical candidates imdusiran and AB-101. The reacquisition of global rights to imdusiran after concluding the partnership with Qilu Pharmaceutical consolidates control over this asset. The company maintains a strong liquidity position with $91.5 million in cash and marketable securities and no debt, supporting ongoing development activities. Royalty entitlements from ONPATTRO and milestone payments contribute to revenue diversification. The recent $2.25 billion settlement related to patent disputes may provide significant non-operating income. Positive analyst sentiment, such as Chardan Capital's maintained buy recommendation, reflects some market confidence.

Arbutus faces significant risks from patent litigation and intellectual property challenges, including a recent European patent revocation that led to a 19% share price decline. The company has incurred substantial net losses and continues to rely on external funding sources, with no assurance of availability on favorable terms. The cessation of discovery and in-house research may limit future innovation. Regulatory approvals and market acceptance of its product candidates remain uncertain. The contingent consideration liability and restructuring costs reflect ongoing financial and operational challenges. Competitive pressures and technological developments in the biotech sector may impact the company's prospects.

Arbutus's moat is anchored in its proprietary lipid nanoparticle (LNP) technology platform, which underpins its RNAi therapeutic candidates and is licensed to partners such as Alnylam. The company benefits from royalty streams on commercialized products like ONPATTRO, providing a recurring revenue source. Its intellectual property portfolio, including patents and licenses, is a critical asset, though it faces ongoing challenges and revocations that could impact exclusivity. The company's focused clinical pipeline and strategic partnerships contribute to its competitive positioning, but the biotech sector's inherent risks and the need for successful product development and regulatory approvals temper the moat strength.

• Patent and Intellectual Property Risks: Arbutus faces ongoing challenges to its patents, including revocations and litigation, which could limit its ability to protect its technology and commercialize products.
• Regulatory Approval Uncertainty: The company’s ability to generate product revenue depends on successful completion of clinical trials and obtaining regulatory approvals, which are inherently uncertain.
• Funding and Liquidity Risks: Arbutus requires substantial additional funding to advance its pipeline; failure to secure adequate financing could delay or reduce development programs.
• Market Acceptance and Commercialization Risks: Even with regulatory approval, products may not achieve sufficient market acceptance among physicians, patients, and payors, impacting revenue potential.
• Operational Risks from Restructuring: Recent workforce reductions and cessation of in-house research may affect the company’s capacity for innovation and development.

• Arbutus Biopharma Corp is a biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (cHBV) infection and other liver diseases.
• The company has ceased all discovery efforts and in-house scientific research as of 2025, focusing on advancing clinical development of two main product candidates: imdusiran and AB-101.
• Arbutus had a strategic partnership with Qilu Pharmaceutical for imdusiran in Greater China and Taiwan, which was mutually concluded in June 2025, with Arbutus regaining global rights to imdusiran.
• The company has a royalty entitlement on ONPATTRO, a drug developed by Alnylam that incorporates Arbutus's lipid nanoparticle (LNP) technology, including a portion sold to OMERS with reversion rights.
• Arbutus's revenue in fiscal year 2025 was $14.1 million, primarily from collaborations, licenses, and royalties, up from $6.2 million in 2024.
• The company reported a net loss of $33.5 million for the year ended December 31, 2025, a reduction from a $69.9 million loss in 2024.
• Operating expenses decreased significantly in 2025 compared to 2024, with research and development expenses down due to organizational streamlining and halting certain clinical trial preparations.
• As of December 31, 2025, Arbutus had $18.0 million in cash and cash equivalents and $73.5 million in short-term investments, totaling $91.5 million in liquid assets, with no outstanding debt.
• The company has a contingent consideration liability related to a 2014 acquisition, valued at $8.4 million as of December 31, 2025, reflecting sales-based milestones and royalties.
• Arbutus is entitled to receive payments from a $950 million noncontingent settlement with Moderna, due by July 8, 2026, plus up to $1.3 billion in contingent payments related to patent litigation.
• The company has implemented workforce reductions and restructuring costs in 2024 and 2025 to focus resources on key clinical programs.
• Arbutus's liquidity ratios as of December 31, 2025, were strong, with a current ratio of 15.73 and a cash ratio of 15.23, indicating substantial short-term financial flexibility.
• The company finances operations through equity sales, collaborations, licenses, royalty monetization, interest income, and government grants.
• Arbutus faces risks related to patent challenges, regulatory approvals, market acceptance of products, and the need for additional funding to advance development programs.
• Recent news highlights include a $2.25 billion settlement deal involving patent disputes with Moderna and Roivant, impacting Arbutus and related companies.
• Arbutus shares fell 19% following a European patent revocation, indicating ongoing intellectual property challenges.
• The company reported a 529% surge in Q2 revenue in 2025, reflecting milestone payments and collaboration income.
• Chardan Capital maintained a buy recommendation on Arbutus in November 2025, reflecting some positive market sentiment.
• Arbutus has been active in reacquiring rights to its product imdusiran in Greater China, ending its partnership with Qilu Pharmaceutical.
• The company reported a Q1 2025 loss but topped revenue estimates, showing some operational progress.
• Arbutus's business model includes licensing its proprietary LNP technology and developing RNA interference (RNAi) therapeutics.
• The company recognizes revenue from collaborations and licenses over time, including upfront fees, milestones, and royalties.
• Arbutus's contingent consideration liability valuation involves significant judgment and assumptions about commercialization probabilities and timing.
• The company has no outstanding debt as of December 31, 2025, supporting its financial stability.
• Arbutus's restructuring in 2025 included exiting its corporate headquarters and discontinuing in-house scientific research.
• The company has a history of issuing common shares to finance operations, with no issuance under its Open Market Sale Agreement in 2025.
• Arbutus's net cash used in operating activities decreased in 2025 compared to 2024, reflecting cost management and strategic focus.
• The company holds investments in US Treasury bills and government bonds as part of its marketable securities portfolio.
• Arbutus's royalty revenue includes payments from Alnylam's ONPATTRO sales and a separate royalty from Acuitas Therapeutics.
• The company is exposed to risks from patent litigation, regulatory decisions, and competitive developments in biotechnology.
• Arbutus's management uses net loss as a key performance metric and monitors cash burn closely.
• The company has recognized non-cash stock compensation modification expenses related to restructuring.
• Arbutus's financial statements are audited by Ernst & Young LLP, with an unqualified opinion as of the 2025 fiscal year.
• The company has a single reportable segment focused on its biopharmaceutical development activities.